Skip to content
TrialScanner

NCT03658629

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Phase 2TerminatedNVAXLead

Registry record

Lead sponsor
Novavax
Conditions
Influenza, Human
Primary completion
Apr 26, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03658629 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03658629: Phase 2 Dose and Formulation... | TrialScanner